Experts discuss how bispecifics might be incorporated earlier in the lines of treatment for certain cancers, the steps that can be taken to improve access to bispecific therapies in underserved or ...

Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...

The Swiss biopharmaceutical company Light Chain Bioscience has developed a novel and unique class of human, bispecific antibodies dubbed κλ bodies, so-called because they combine a κ light ...